Taken together, our data suggest that purinergic signaling enhances the initial Ca2+ events during CD8+ T cell activation and plays an essential role in the refinement of the downstream effector function, providing advanced possibilities for clinical interventions, for example, in the tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.